Entering text into the input field will update the search result below

Achieve Life Sciences: All Eyes On Phase 3 Data For Smoking Cessation Drug

Jan. 28, 2023 11:45 PM ETAchieve Life Sciences, Inc. (ACHV)PFE9 Comments
BiotechValley Insights profile picture
BiotechValley Insights


  • ORCA-2 phase 3 trial was a success where Cytisinicline has shown statistically significant improvement in quit rates and robust safety profile.
  • Phase 3 ORCA-3 registration trial is ongoing, and we expect the data readout in 2Q 2023; we expect the results to be positive.
  • The company has received $18.9m private placement and secured a patent around the formulation of the drug, further de-risking the stock.
  • We reiterate buy rating.
Depressed girl smoking on a bench

Mixmike/iStock via Getty Images

Our take in 2023

Since we initiated Achieve Life Sciences (NASDAQ:ACHV) back in April last year, there have been many positive newsflows that happened to the company. This article is a short update of my views on the company. The biggest news

This article was written by

BiotechValley Insights profile picture
We publish unbiased long/short trade ideas. Please follow our Twitter page: https://twitter.com/biotechvalley_i

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Biotechvalley Insight (BTVI) is a group of biotech/technology investors with a main interest in US-based small/mid-cap biotech companies and cryptocurrencies. We are not affiliated with any institution/company but an independent research organization of students/working professionals. Biotechvalley Insights (BTVI) is not a registered investment advisor, and articles are not targeted toward retail investors. The content is for informational purposes only; you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in our articles or comments constitutes a solicitation, recommendation, endorsement, or offer by Biotechvalley Insights or any third-party service provider to buy or sell any securities or other financial instruments in this or in any other jurisdiction in which such solicitation or offer would be unlawful under the securities laws of such jurisdiction. The research and reports made available by BTVI reflect and express the opinion of the applicable BTVI entity as of the time of the report only. Reports are based on generally-available information, field research, inferences, and deductions through the applicable due diligence and analytical process. BTVI may use resources from brokerage reports, corporate IR, and KOL/expert interviews that may have a conflict of interest with the company/assets that BTVI covers. To the best of the applicable BTVI's ability and belief, all information contained herein is accurate and reliable, is not material non-public information, and has been obtained from public sources that the applicable BTVI entity believes to be accurate and reliable. However, such information is presented “as is” without warranty of any kind, whether express or implied. With respect to their respective research reports, BTVI makes no representation, express or implied, as to the accuracy, timeliness, or completeness of any such information or with regard to the results to be obtained from its use. Further, any analysis/comment contains a very large measure of analysis and opinion. All expressions of opinion are subject to change without notice, and BTVI does not undertake to update or supplement any reports or any of the information, analysis, and opinion contained in them.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

Comments (9)

Phase 3 is complete and being published soon. It appears to have been a success. If/when they get FDA approval in June or July, this will be a huge winner. Long 20,000 shares
pat45 profile picture
tiny market cap... Idea when it gets to market?? I know many who would try product
shake shake money tree profile picture
I wonder if someone could explain the following slides:


Slide #18 and #19. The placebo quit rate seems quite inconsistent and they are from the SAME pool of placebo data. For example, on #18, week 9-12 quit rate is 7% but week 3-6 quit rate on #19 is only 4.4%. I would assume that most people quit smoking at the beginning of the trial and then they gradually revert back to smoking again.
Pili_Drive01 profile picture
Finally, a followup to Champix. Smoking is still prevalent as ever with emphysema and chronic bronchitis still killing people all around the world. While GSK and others make more inhalers.
shake shake money tree profile picture
According to chart, this stock dropped 99.98% since 10 years ago.
@shake shake money tree maybe do some research? The stock didn't exist 10 years ago. They were brought public through a reverse merger with OncoGenex in 2017. Takes literally 5 minutes to find that out.
shake shake money tree profile picture
@Tcardizzle33 Thank you for the 5 minutes research.
@shake shake money tree i guess you have a point but I'm not buying the stock on the price of ten years ago Im buying at this time I guess your shorting it been tough two week for you
Disagree with this article? Submit your own. To report a factual error in this article, . Your feedback matters to us!
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.